Filtered By:
Drug: Proton Pump Inhibitors PPIs

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 238 results found since Jan 2013.

Proton Pump Inhibitors and Dementia Incidence
To the Editor I read with interest the article by Gomm et al investigating the association of proton pump inhibitors and dementia. The authors are to be commended for their large data set, analysis, and detailed proposed pathophysiologic mechanism by which this association might occur. However, 2 important medical comorbidities seem to be missing from their study: gastroesophageal reflux disease and obstructive sleep apnea. Both of these comorbidities can cause cognitive issues, especially in those with apolipoprotein E genetic variants and those who have had a stroke. Gastroesophageal reflux disease would constitute the r...
Source: JAMA Neurology - June 20, 2016 Category: Neurology Source Type: research

The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study
Conclusions: Our results demonstrated a decreased risk of DM in UGID patients who used PPIs; the risk appeared to be significantly dose-dependent.
Source: Medicine - July 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study Health Services and Outcomes Research
ConclusionsPPIs did not significantly affect the MACE and bleeding risk associated with prasugrel use, relative to clopidogrel.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01088503.
Source: JAHA:Journal of the American Heart Association - September 27, 2016 Category: Cardiology Authors: Jackson, L. R., Peterson, E. D., McCoy, L. A., Ju, C., Zettler, M., Baker, B. A., Messenger, J. C., Faries, D. E., Effron, M. B., Cohen, D. J., Wang, T. Y. Tags: Quality and Outcomes Original Research Source Type: research

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs. METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research

Your NEJM Group Today: Climate Change and Health Interview / PPIs & Stroke / New York Hospitalist Opportunities (FREE)
By the Editors Check out today ' s selections from NEJM Group: NEJM Audio Interview: Climate Change and Health: Dr. …
Source: Physician's First Watch current issue - April 26, 2017 Category: Primary Care Source Type: news

The risk of lower gastrointestinal bleeding in low ‐dose aspirin users
ConclusionsThe risk of LGIB was higher in low‐dose aspirin users than in aspirin nonusers in this nationwide cohort. Low‐dose aspirin, NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for LGIB.
Source: Alimentary Pharmacology and Therapeutics - April 27, 2017 Category: Drugs & Pharmacology Authors: W. ‐C. Chen, K.‐H. Lin, Y.‐T. Huang, T.‐J. Tsai, W.‐C. Sun, S.‐K. Chuah, D.‐C. Wu, P.‐I. Hsu Tags: Original Article Source Type: research

Helicobacter pylori infection: old and new.
Authors: Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbințeanu-Braticevici C Abstract Helicobacter pylori is a spiral-shaped bacterium that grows in the digestive tract and may be present in more than half of the world's population. The clinical features of Helicobacter pylori range from asymptomatic gastritis to gastrointestinal malignancy. Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell marginal zone lymphoma and Helicobacter pylori has been detected in more than 75% of the patients with MALT lymphoma. Many tests for the detection of Helicobacter pylori are available, including antibo...
Source: Journal of Medicine and Life - June 17, 2017 Category: General Medicine Tags: J Med Life Source Type: research

Heartburn drugs linked to premature death
Conclusion This larger set of observational data finds that PPI drugs are associated with an increase in the risk of early death compared with either H2 blockers or no acid suppression drugs. This was the case for participants both with and without gastrointestinal problems. It also appears as though the longer the PPIs drugs are taken, the greater the risk of death. Considering that these drugs are widely used in the UK, these findings may cause concern. But the research has a number of important limitations: The study was conducted in a population of mostly white, older US male veterans, which might limit the ability...
Source: NHS News Feed - July 4, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
Conclusions PPI administration significantly decreased the trough and peak DCs in patients with NVAF. Therefore, when prescribing PPIs for patients with NVAF in a clinical setting, the possibility that the bioavailability of dabigatran may decrease should be considered.
Source: Journal of Arrhythmia - October 13, 2017 Category: Cardiology Source Type: research

PFO Closure Reduces Strokes, and PPIs Increase Dementia Risk? PFO Closure Reduces Strokes, and PPIs Increase Dementia Risk?
New research suggests that reducing patent foramen ovale size could lessen stroke risk, while other work explores the role that PPIs might play in causing dementia.Medscape Neurology
Source: Medscape Today Headlines - October 17, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news

Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis.
Abstract Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs. Even if PPI are usually considered as safe, there is a growing concern for a range of adverse effects of chronic PPI therapy often in the absence of appropriate indications. We propose, after a summary of renal, cardiovascular and neurological complications (dementia, chronic kidney disease, myocardial infarction and stroke), an integrative overview of the potential biological mechanisms involved. Eleven positive pharmacoepidemiological studies, mainly based on health insurance database linkage to hospital database, reported an ...
Source: Therapie - October 14, 2017 Category: Psychiatry & Psychology Authors: Kheloufi F, Frankel D, Kaspi E, Lepelley M, Mallaret M, Boucherie Q, Roll P, Micallef J Tags: Therapie Source Type: research

Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis.
CONCLUSION: In this large cohort of real-world patients, the combination of PPIs with DAPT was not associated with increased risk of MACCE in patients who underwent PCI at up to 2 years of follow-up. PMID: 29237921 [PubMed - in process]
Source: Chinese Medical Journal - December 15, 2017 Category: General Medicine Authors: Zhu P, Gao Z, Tang XF, Xu JJ, Zhang Y, Gao LJ, Chen J, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ Tags: Chin Med J (Engl) Source Type: research

New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study
ConclusionsGastrointestinal bleeding increased the risk of subsequent mortality during follow‐up of anticoagulated patients, highlighting the importance of prevention. The study developed a new scoring model for acute GI bleeding risk based on five factors (no‐proton pump inhibitor use, chronic kidney disease, chronic obstructive pulmonary disease, history of peptic ulcer disease, and liver cirrhosis), which was superior to the HAS‐BLED score.
Source: Journal of Gastroenterology and Hepatology - December 28, 2017 Category: Gastroenterology Authors: Akira Shimomura, Naoyoshi Nagata, Takuro Shimbo, Toshiyuki Sakurai, Shiori Moriyasu, Hidetaka Okubo, Kazuhiro Watanabe, Chizu Yokoi, Junichi Akiyama, Naomi Uemura Tags: Gastroenterology Source Type: research

Your NEJM Group Today: Acute Pyelonephritis Clinical Pearls / PPIs & Stroke? / Connecticut Primary Care Opportunities
Here ' s what we chose for you from NEJM Group today: NEJM Resident 360: Clinical Pearls: What are the typical manifestations of acute pyelonephritis? What is...
Source: Physician's First Watch current issue - January 8, 2018 Category: Primary Care Source Type: news

Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel
The objective of the present study was to examine the robustness of this interaction using a well-controlled study design in a population of participants free of confounders.
Source: Journal of Stroke and Cerebrovascular Diseases - February 12, 2018 Category: Neurology Authors: Eugene R. Przespolewski, Erica S. Westphal, Michelle Rainka, Nicholas M. Smith, Vernice Bates, Fran M. Gengo Source Type: research